[Pharmaceutical treatment for patients with hip fracture].
It is well known that fracture risk, including second hip fracture, is elevated in patients with hip fracture. Therefore, they are good candidate for pharmaceutical treatment of osteoporosis to prevent subsequent fractures. Nitrogen-containing bisphosphonate is the first line drug for their treatment. Teriparatide, which has been recently approved in Japan for the treatment of osteoporosis, has osteogenic effects and is expected to prevent fractures in patients with hip fracture.
Hagino
Hiroshi
H
School of Health Science, Faculty of Medicine,/Rehabilitation Division, Tottori University.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D011379:Prognosis; D012306:Risk; D055502:Secondary Prevention; D019379:Teriparatide / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide